CANY
PTGX icon

Caxton Associates (New York)’s Protagonist Therapeutics PTGX Stock Holding History

Caxton Associates (New York)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,047
Closed -$464K – 577
2024
Q1 		$464K Buy
+16,047
New +$437K 0.03% 332
2023
Q1 		– Sell
-21,853
Closed -$238K – 609
2022
Q4 		$238K Buy
+21,853
New +$184K 0.02% 354
2022
Q3 		– Sell
-61,370
Closed -$485K – 629
2022
Q2 		$485K Buy
+61,370
New +$742K 0.05% 282

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Caxton Associates (New York)'s PTGX Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 16,047 shares — an estimated $464K sold.

Caxton Associates (New York) first reported a position in PTGX in Q2 2022 and held it in 3 quarters. The position peaked at $485K in Q2 2022. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 16,047 Protagonist Therapeutics shares in Q2 2024, an estimated $464K.
  • Caxton Associates (New York) first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 3 quarters.
  • Caxton Associates (New York)'s Protagonist Therapeutics position peaked at $485K in Q2 2022.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.